Transcenta Holding Past Earnings Performance
Past criteria checks 0/6
Transcenta Holding has been growing earnings at an average annual rate of 14.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 6.1% per year.
Key information
14.4%
Earnings growth rate
50.5%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | -6.1% |
Return on equity | -39.8% |
Net Margin | -1,606.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Transcenta Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 22 | -359 | 96 | 277 |
31 Mar 24 | 38 | -411 | 108 | 330 |
31 Dec 23 | 54 | -463 | 119 | 382 |
30 Sep 23 | 85 | -451 | 115 | 385 |
30 Jun 23 | 116 | -440 | 112 | 387 |
31 Mar 23 | 109 | -424 | 112 | 369 |
31 Dec 22 | 102 | -407 | 112 | 350 |
30 Sep 22 | 74 | -666 | 137 | 349 |
30 Jun 22 | 45 | -925 | 161 | 348 |
31 Mar 22 | 53 | -1,748 | 153 | 383 |
31 Dec 21 | 50 | -1,716 | 147 | 344 |
30 Sep 21 | 65 | -1,457 | 153 | 317 |
30 Jun 21 | 79 | -1,199 | 160 | 290 |
31 Mar 21 | 82 | -364 | 166 | 223 |
31 Dec 20 | 81 | -317 | 158 | 200 |
31 Dec 19 | 44 | -395 | 123 | 215 |
Quality Earnings: 6628 is currently unprofitable.
Growing Profit Margin: 6628 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6628 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare 6628's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6628 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.4%).
Return on Equity
High ROE: 6628 has a negative Return on Equity (-39.76%), as it is currently unprofitable.